Drug Profile
Anti-Clostridium difficile monoclonal antibodies - AstraZeneca
Alternative Names: C.difficile antibody therapy - Progenics PharmaceuticalsLatest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Progenics Pharmaceuticals
- Developer MedImmune
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections; Diarrhoea
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 16 Feb 2016 No development reported - Phase-II for Clostridium difficile infections in USA (Parenteral)
- 16 Feb 2016 No development reported - Phase-II for Diarrhoea in USA (Parenteral)